The first generic version of the Advair Diskus inhaler widely used for asthma and chronic obstructive pulmonary disease (COPD) has been approved by the US Food and Drug Administration.

This endorsement "is part of our long-standing commitment to improving access to high-quality, low-cost generic alternatives," said Dr. Janet Woodcock, Director of the Center for Evaluation and Disability. search for drugs from the FDA.

"People living with asthma and COPD are all too aware of the critical importance of having access to the treatment they need to feel better." Today's approval ####################################################################################### It will intensify competition in the market, which will ultimately benefit patients who depend on this drug, "said Woodcock. Wednesday in a press release from the agency.

The new inhaler from drug manufacturer Mylan contains fluticasone propionate and salmeterol inhalation powder. It is approved for the treatment of asthma twice daily in patients aged 4 years and older. In cases of COPD, it is approved for maintenance treatment of airway obstruction and to reduce exacerbations.

Asthma is a chronic lung disease that inflames and shrinks the airways. We know that more than 26 million people in the United States are affected, including about 7 million children, the FDA said.

COPD is a progressive lung disease that affects breathing and often worsens over time. Symptoms may include a cough that produces large amounts of mucus, wheezing, shortness of breath, and tightness in the chest.

The inhaler is available in three concentrations: fluticasone propionate 100 μg / salmeterol 50 μg; fluticasone propionate 250 μg / salmeterol 50 μg; and fluticasone propionate at 500 μg / salmeterol at 50 μg.

In asthmatic patients, the most common side effects of this combination therapy are: infection or inflammation of the upper respiratory tract; swelling in the back of the throat; hoarseness or difficulty speaking; oral thrush, also called candidiasis; bronchitis; cough; headache; nausea and vomiting.

In patients with COPD, the most common side effects are: pneumonia; oral candidiasis; irritation of the throat; hoarseness or difficulty speaking; viral respiratory infections; headache; and musculoskeletal pain.